AXSM240719P67500
- 0.63
- 0.000.00%
Axsome Therapeutics Newsroom
Mizhuo's Top Picks in Healthcare for July
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Morgan Stanley analyst Vikram Purohit maintains $Axsome Therapeutics(AXSM.US)$ with a buy rating, and maintains the target price at $115.According to TipRanks data, the analyst has a success rate of 2
ResMed, Philips Under Pressure as Eli Lilly Seeks Sleep Indication for Weight Loss Drug
Investors Ignore Increasing Losses at Axsome Therapeutics (NASDAQ:AXSM) as Stock Jumps 7.0% This Past Week
Citi's North America Focus List Updated, Adds: Coca-Cola, Evergy, Etc.
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $106 to $125
On Jun 12, major Wall Street analysts update their ratings for $Axsome Therapeutics(AXSM.US)$, with price targets ranging from $106 to $125.Morgan Stanley analyst Vikram Purohit maintains with a buy r
Investors Push Axsome Therapeutics (NASDAQ:AXSM) 4.1% Lower This Week, Company's Increasing Losses Might Be to Blame
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well o
Mizuho Reiterates Buy on Axsome Therapeutics, Maintains $106 Price Target
Mizuho analyst Graig Suvannavejh reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $106 price target.
Axsome Therapeutics Shares Continue To Fall
Express News | Axsome Therapeutics Shares Are Trading Lower After Culper Research Issued a Short Report on the Stock
Express News | Watching Axsome Therapeutics Shares, Culper Research Issues Short Report
Express News | Axsome Therapeutics Shares Down 6% Premarket After Culper Research Says Short on Co
Express News | Culper Research Says Short on Axsome Therapeutics
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $190
H.C. Wainwright analyst Ram Selvaraju maintains $Axsome Therapeutics(AXSM.US)$ with a buy rating, and maintains the target price at $190.According to TipRanks data, the analyst has a success rate of 3
Express News | HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $190 Price Target
15 Analysts Assess Axsome Therapeutics: What You Need To Know
Throughout the last three months, 15 analysts have evaluated Axsome Therapeutics (NASDAQ:AXSM), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent r
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
Axsome Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/05/2024 79.51% RBC Capital $127 → $130 Maintains Outperform 05/08/2024 46.37% Mizuho $109 → $106 Mainta
Express News | Axsome Therapeutics Announced That It Has Entered Into A Settlement Agreement With Unichem Laboratories Ltd. Resolving Patent Litigation Related To Axsome's Product Sunosi (Solriamfetol)
Axsome Therapeutics: Settlement Agreement Permits Unichem to Begin Selling Its Generic Version of Sunosi on June 30, 2042, or Earlier Under Certain Circumstances >AXSM
Axsome Therapeutics: Settlement Agreement Permits Unichem to Begin Selling Its Generic Version of Sunosi on June 30, 2042, or Earlier Under Certain Circumstances >AXSM